ERAVACYCLINE IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: A REAL-WORLD STUDY OF DRUG-DRUG INTERACTIONS WITH CYCLOSPORINE/TACROLIMUS AND ANTI-INFECTIVE EFFICACY (EHA 2026) - May 13, 2026 - Abstract #EHA-3603; PB4016; "Eravacycline, a novel synthetic tetracycline, shares the CYP3A4 metabolic pathway with CNIs, yet comprehensive data on their potential pharmacokinetic interactions are scarce...These trends persisted in patients receiving concomitant azoles/ letermovir and in those with non-terminal status and grade 0–2 liver and kidney function...In the post-transplant setting, eravacycline demonstrated robust anti-infective efficacy with an acceptable safety profile. Changes in CNI concentration-to-dose (C/D) Before and After Eravacycline Coadministration"
Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Neutropenia • Transplantation • CYP3A4
|
|
Jieya Luo 1; Jingqi Li 1; Xinhui Zheng 1; Xin Chen 1; Erlie Jiang1
|